DK0600930T3 - Diagnose og behandling af autoimmune sygdomme - Google Patents

Diagnose og behandling af autoimmune sygdomme

Info

Publication number: DK0600930T3
Authority: DK; Denmark
Prior art keywords: diagnosis; treatment; autoimmune diseases; mhc class; antigen
Prior art date: 1991-08-02

Application number

DK92916542T

Other languages

English (en)

Inventor

Denise L Faustman

Original Assignee

Denise L Faustman

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-02

Filing date

1992-07-28

Publication date

2002-12-02

1992-07-28 Application filed by Denise L Faustman filed Critical Denise L Faustman

2002-12-02 Application granted granted Critical

2002-12-02 Publication of DK0600930T3 publication Critical patent/DK0600930T3/da

Links

208000023275 Autoimmune disease Diseases 0.000 title abstract 2
238000003745 diagnosis Methods 0.000 title 1
102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 abstract 3
101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 1
230000030741 antigen processing and presentation Effects 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Zoology (AREA)
Diabetes (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Rehabilitation Therapy (AREA)
General Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Transplantation (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)

DK92916542T 1991-08-02 1992-07-28 Diagnose og behandling af autoimmune sygdomme DK0600930T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73987891A	1991-08-02	1991-08-02
US81051791A	1991-12-19	1991-12-19
PCT/US1992/006248 WO1993002690A1 (en)	1991-08-02	1992-07-28	Diagnosis and treatment of autoimmune diseases

Publications (1)

Publication Number	Publication Date
DK0600930T3 true DK0600930T3 (da)	2002-12-02

Family

ID=27113589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92916542T DK0600930T3 (da)	1991-08-02	1992-07-28	Diagnose og behandling af autoimmune sygdomme

Country Status (9)

Country	Link
US (1)	US5538854A (da)
EP (2)	EP1298203A3 (da)
JP (2)	JPH06510903A (da)
AT (1)	ATE225397T1 (da)
CA (1)	CA2114647A1 (da)
DE (1)	DE69232798T2 (da)
DK (1)	DK0600930T3 (da)
ES (1)	ES2181676T3 (da)
WO (1)	WO1993002690A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU692152B2 (en) *	1993-03-17	1998-06-04	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
CA2158932A1 (en) *	1993-09-03	1995-03-09	Douglas J. Jolly	Methods of suppressing autoimmune response
US5674487A (en) *	1994-09-28	1997-10-07	Univ Jefferson	Method for treating autoimmune diseases
US6033661A (en)	1995-06-07	2000-03-07	Thomas Jefferson University	Composition and method for allogenetic mononuclear cell immunotherapy
US5753625A (en) *	1995-05-12	1998-05-19	Sangstat Medical Corporation	Treatment for inhibiting the progression of autoimmune disease
US5856446A (en) *	1995-07-07	1999-01-05	Autoimmune Inc.	Method of treating rheumatoid arthritis with low dose type II collagen
US5792604A (en) *	1996-03-12	1998-08-11	University Of British Columbia	Method of identifying MHC-class I restricted antigens endogenously processed by cellular secretory pathway
AU773591B2 (en) *	1996-08-23	2004-05-27	University Of Florida Research Foundation, Inc.	Materials and methods for detection and treatment of immune system dysfunctions
US5939069A (en)	1996-08-23	1999-08-17	University Of Florida	Materials and methods for detection and treatment of immune system dysfunctions
US6617171B2 (en) *	1998-02-27	2003-09-09	The General Hospital Corporation	Methods for diagnosing and treating autoimmune disease
US6284879B1 (en)	1998-04-16	2001-09-04	The General Hospital Corporation	Transport associated protein splice variants
US6303325B1 (en)	1998-05-29	2001-10-16	Dade Behring Inc.	Method for detecting analytes
US6599710B1 (en) *	1999-03-10	2003-07-29	The General Hospital Corporation	Treatment of autoimmune disease
SE521031C2 (sv) *	1999-05-05	2003-09-23	Srinivas Uppugunduri	Nya specifika inhibitorer av akut och kronisk inflammation
US7084256B2 (en) *	1999-09-24	2006-08-01	Large Scale Biology Corporation	Self antigen vaccines for treating B cell lymphomas and other cancers
US20030039659A1 (en) *	1999-09-24	2003-02-27	Mccormick Alison A.	Self antigen vaccines for treating B cell lymphomas and other cancers
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US7628988B2 (en)	2002-06-27	2009-12-08	The General Hospital Corporation	Methods and compositions for treating type 1 diabetes
US7582313B2 (en)	2002-06-27	2009-09-01	The General Hospital Corporation	Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20050084967A1 (en)	2002-06-28	2005-04-21	Xcyte Therapies, Inc.	Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
GB0305796D0 (en) *	2002-07-24	2003-04-16	Micromass Ltd	Method of mass spectrometry and a mass spectrometer
WO2004045376A2 (en) *	2002-11-15	2004-06-03	The General Hospital Corporation	Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) *	2005-01-18	2008-05-01	Faustman Denise L	Compositions Containing Agm Cells And Methods Of Use Thereof
EP3936137A1 (en)	2013-02-07	2022-01-12	The General Hospital Corporation	Methods for expansion or depletion of t-regulatory cells
CN111879948A (zh)	2013-10-17	2020-11-03	综合医院公司	鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CN115043943A (zh)	2015-05-15	2022-09-13	综合医院公司	拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en)	2015-08-28	2019-05-09	The General Hospital Corporation	Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (en)	2015-09-29	2024-03-06	The General Hospital Corporation	A composition comprising bcg for reducing cholesterol.
US11859002B2 (en)	2016-05-13	2024-01-02	The General Hospital Corporation	Antagonistic anti-tumor necrosis factor receptor 2 antibodies
CN113302205B (zh)	2018-11-15	2024-12-06	综合医院公司	激动性肿瘤坏死因子受体超家族多肽

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3608608A1 (de) *	1985-06-18	1986-12-18	Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim	Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von autoimmunerkrankungen, viruserkrankungen und malignen erkrankungen des menschen in niedriger dosierung
WO1990010016A1 (en) *	1989-03-03	1990-09-07	The Regents Of The University Of California	Class i mhc modulation of surface receptor activity

1992
- 1992-07-28 DE DE69232798T patent/DE69232798T2/de not_active Expired - Fee Related
- 1992-07-28 DK DK92916542T patent/DK0600930T3/da active
- 1992-07-28 WO PCT/US1992/006248 patent/WO1993002690A1/en not_active Ceased
- 1992-07-28 CA CA002114647A patent/CA2114647A1/en not_active Abandoned
- 1992-07-28 EP EP02078961A patent/EP1298203A3/en not_active Withdrawn
- 1992-07-28 AT AT92916542T patent/ATE225397T1/de not_active IP Right Cessation
- 1992-07-28 JP JP5503677A patent/JPH06510903A/ja not_active Withdrawn
- 1992-07-28 EP EP92916542A patent/EP0600930B1/en not_active Expired - Lifetime
- 1992-07-28 ES ES92916542T patent/ES2181676T3/es not_active Expired - Lifetime
1993
- 1993-07-14 US US08/096,941 patent/US5538854A/en not_active Expired - Lifetime
2005
- 2005-01-19 JP JP2005011425A patent/JP2005179371A/ja active Pending

Also Published As

Publication number	Publication date
US5538854A (en)	1996-07-23
EP0600930A1 (en)	1994-06-15
CA2114647A1 (en)	1993-02-18
JP2005179371A (ja)	2005-07-07
DE69232798T2 (de)	2003-07-24
EP1298203A3 (en)	2004-01-21
ATE225397T1 (de)	2002-10-15
EP0600930B1 (en)	2002-10-02
JPH06510903A (ja)	1994-12-08
EP1298203A2 (en)	2003-04-02
WO1993002690A1 (en)	1993-02-18
DE69232798D1 (de)	2002-11-07
EP0600930A4 (en)	1995-01-25
ES2181676T3 (es)	2003-03-01

Publication	Publication Date	Title
DK0600930T3 (da)	2002-12-02	Diagnose og behandling af autoimmune sygdomme
ATE319474T1 (de)	2006-03-15	Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ES2084338T3 (es)	1996-05-01	Anticuerpos recombinantes especificos para el tnf alfa.
DE3854741D1 (de)	1996-01-11	Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
DE69226197D1 (de)	1998-08-13	Hämoglobine als arzneimittelabgabesystem
DE69127470D1 (de)	1997-10-02	Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
DE69033487D1 (de)	2000-04-20	Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
FR2703254B1 (fr)	1998-04-30	Dispositif de traitement thérapeutique d'un tissu pathologique, comportant un cathéter .
DE69108332D1 (de)	1995-04-27	Nadelvorrichtung für medizinische Zwecke.
EP0671920A4 (en)	1996-01-10	AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
DK0497858T3 (da)	1995-06-19	Middel til at tage terapeutiske elastiske strømperpå
EP0674661A4 (en)	1997-12-10	TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS.
DK0522091T5 (da)	2008-06-23	Anvendelse af et MBP-peptid til fremstilling af et medikament til behandling af multipel sklerose
NO175023C (no)	1994-08-17	Fremgangmåte for in vitro diagnostisering av en innflammasjonssykdom indusert av immunkomplekser som er i omlöp, og fremgangsmåte for fremstilling av dsRNA til den in vitro diagnostisering
IT9041503A0 (it)	1990-01-19	Dispositivo per la cura chirurgica dell'ametropia
FI933291A0 (fi)	1993-07-21	Foerfarande foer paovisning av anti-rna-antikroppar
DE3879085D1 (de)	1993-04-15	Snrnp-a-antigen und fragmente davon.
NO880274D0 (no)	1988-01-22	Medisinsk diagnoseanordning.
SE429402B (sv)	1983-09-05	Patientstol for tandbehandlingsendamal
Jacknowitz et al.	1977	Nitrofurantoin polyneuropathy: report of two cases
DE59006159D1 (de)	1994-07-21	Verwendung von macrolactonen als antiallergica.
DE69124415D1 (de)	1997-03-13	Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
ATE63463T1 (de)	1991-06-15	Behandlung chronischer entzuendungskrankheiten.
SU1711817A1 (ru)	1992-02-15	Способ диагностики системной склеродермии
ES2038578T1 (es)	1993-08-01	Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.